Krsnaa DiagnosticsQ2 FY24

Krsnaa Diagnostics Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹518.7P/E: 16.7Market Cap: ₹1.7K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • The company targets a sustained revenue growth of approximately 30% CAGR for FY24 and FY25, excluding the Rajasthan project.
  • FY24 expects around Rs. 600 crores revenue with Rs. 180-200 crores per quarter in FY25.
  • New projects in Odisha, Assam, Maharashtra CT, Himachal Pradesh, and BMC are key growth contributors for FY25.
  • Rajasthan project revenue potential has revised upward to Rs. 300 crores due to district reorganization, though commercialization may shift to FY25.
  • Additional tenders, including a large radiology tender in Andhra Pradesh and others in the pipeline, are expected to add Rs. 140 to Rs. 200 crores top-line by FY25 and beyond.
  • Mature centers and existing projects also expected to grow at 8-30%, supporting overall 30% growth trajectory.
  • B2C business segment gradually scaling up with positive early traction.

See what Krsnaa Diagnostics management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • The transcript from the earnings call on page 22 and surrounding pages does not mention any current or planned fundraising through debt or equity.
  • As of September 30, 2023, the company holds a gross debt of Rs. 109 crores but maintains a net debt-free status with Rs. 236 crores in cash and cash equivalents.
  • No specific references were made to raising additional funds via debt or equity in the near future.
  • The management focuses on organic growth through existing projects and new tenders without highlighting fundraising plans.
  • Any significant capital expenditures, such as on Rajasthan, are currently minimal and expensed rather than capitalized.
  • For inquiries, investors are encouraged to contact the Investor Relations Team, but no fundraising announcements were disclosed in this call.

See what Krsnaa Diagnostics management said on order book — free account, 30 seconds.

Capex plans

Yes
  • The company is investing in setting up new laboratories and collection centers as part of various Public-Private Partnership (PPP) projects across states like Assam, Odisha, Maharashtra (CT project), Himachal Pradesh, and Mumbai (BMC project).
  • They have invested in expanding the Mumbai lab to support the rapid operationalization of around 462 centers under the BMC contract.
  • Ongoing capex includes setting up Radiology centers, Pathology labs, and collection centers which require upfront costs for equipment, manpower, interiors, infrastructure, and logistics.
  • While initial quarters incur higher expenses due to front-loaded investments, these centers typically mature after 2-3 years, leading to improved margins.
  • No significant capitalization has been made for the Rajasthan project yet; only operational expenses have been incurred and expensed out.
  • They expect capex costs to reduce over time as projects mature and ramp up operations, contributing positively to margins going forward.

Track Krsnaa Diagnostics — get its next earnings analysis in your feed

How does Krsnaa Diagnostics rank vs peers in Healthcare Services?

Pro feature
ThisKrsnaa Diagnostics
Rev 2Mar 3

How does Krsnaa Diagnostics rank in Healthcare Services?

Compare Krsnaa Diagnostics against every Healthcare Services company (Q2 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →